Kazia Therapeutics (KZIA) AI Stock Analysis

• Market Cap: $9.03M
• Dividend Yield: N/A
• Average Volume (3M): 56.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: N/A
• EPS Growth: -32.63%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,117,859
• 10 Day Avg. Volume: 18,852
• 30 Day Avg. Volume: 56,192
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $14.00
• Price Target Upside: 79.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 31 Underperform
• Price Target: ―

Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company's unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company's challenges.

Positive Factors

Clinical Trial Success

Encouraging early results from the Phase 1 breast cancer study show a significant reduction in circulating tumor cells for the first patient treated with paxalisib.

Financial Stability

The breast cancer study is funded by investigators and does not require capital investments from Kazia, which is beneficial for the company's financial stability.

Market Opportunity

Paxalisib is being evaluated for treating resistant triple negative breast cancer, which presents a significant market opportunity, and data from this study could be impactful.

Negative Factors

Commercialization Delay

There is a delay in the potential commercialization of paxalisib for the treatment of GBM and DIPG due to delays in the clinical programs.

Financing Risk

Phase 3 for glioblastoma multiforme (GBM) has not yet initiated and is financing dependent, which poses a risk for future developments.

Market Conditions

The financing market remains difficult due to current market conditions and Kazia’s market cap.

Kazia Therapeutics Business Overview & Revenue Model

Company Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

How the Company Makes Money

Kazia Therapeutics primarily generates revenue through the development and potential commercialization of its drug candidates. The company seeks to advance its therapies through clinical trials and, upon successful results and regulatory approval, aims to license its drugs to larger pharmaceutical companies or bring them to market directly. Key revenue streams include milestone payments, royalties from licensing agreements, and potential sales revenue of approved drugs. Partnerships with research institutions and pharmaceutical companies also play a crucial role in funding and advancing their drug development programs.

Kazia Therapeutics Financial Statement Overview

Summary

Kazia Therapeutics is facing financial challenges with declining revenues, persistent losses, and negative equity. The company struggles with cash flow generation and financial stability, which could affect its ability to sustain operations without significant changes or external funding.

Income Statement

Kazia Therapeutics has shown declining revenue over the years with a significant drop in total revenue in the most recent period. The company is experiencing a negative net profit margin, indicating it is not profitable. Moreover, both EBIT and EBITDA margins are negative, highlighting operational inefficiencies and challenges in controlling costs.

Balance Sheet

The company's financial structure is concerning, with negative stockholders' equity in the latest period, indicating liabilities exceed assets. The debt-to-equity ratio is not applicable due to negative equity, which poses a financial risk. Moreover, the equity ratio is negative, underscoring the financial instability and leverage issues.

Cash Flow

There is a negative operating cash flow and free cash flow, indicating that the company is not generating sufficient cash from its operations. The free cash flow growth rate is negative, suggesting worsening liquidity and inability to cover expenses without external financing.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	2.31M	555.00	25.00	15.18M	1.06K
Gross Profit	2.31M	555.00	25.00	15.18M	1.06K
EBITDA	-26.77M	-22.28M	-23.51M	-5.11M	-11.11M
Net Income	-26.78M	-20.47M	-24.65M	-8.42M	-12.47M
Balance Sheet
Total Assets	21.59M	28.09M	34.96M	58.09M	23.06M
Cash, Cash Equivalents and Short-Term Investments	1.66M	5.24M	7.36M	27.59M	8.76M
Total Debt	634.00K	1.80M	1.84M	0.00	0.00
Total Liabilities	31.60M	16.03M	16.32M	20.24M	8.94M
Stockholders Equity	-10.02M	12.05M	18.64M	37.85M	14.13M
Cash Flow
Free Cash Flow	-9.58M	-15.16M	-22.76M	-9.11M	-8.81M
Operating Cash Flow	-9.58M	-15.16M	-22.76M	-9.11M	-8.81M
Investing Cash Flow	0.00	0.00	-2.36M	0.00	0.00
Financing Cash Flow	5.99M	12.97M	3.73M	28.11M	12.14M

Kazia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 7.81
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Neutral. The current price of 7.81 is below the 20-day moving average (MA) of 8.00, below the 50-day MA of 8.35, and below the 200-day MA of 9.07, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 47.15 is Neutral, neither overbought nor oversold. The STOCH value of 59.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KZIA.

Kazia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
SONN	49 Neutral	$24.38M	―	-714.96%	―	1689.52%	66.05%
BDRX	45 Neutral	$373.07K	―	-89.21%	―	-100.00%	96.37%
XBIO	43 Neutral	$4.46M	―	-51.83%	―	-2.94%	34.52%
KZIA	31 Underperform	$9.03M	―	-3028.18%	―	―	-32.63%
NLSP	―	$7.70M	―		―	―	―
KTTA	―	$5.24M	―	-85.84%	―	―	―